AstraZeneca plans new Oxford vaccine trial to prove jab works on all ages
More volunteers will be recruited to test half-dose regimen as critics question latest results
A fresh global trial of the Oxford Covid-19 vaccine is being launched to clarify how effectively the jab protects older age groups - and banish doubts that have emerged since preliminary results were published on Monday.
“The company wants the new test to confirm the 90% efficacy rate that the shot showed in a portion of an existing trial,” Bloomberg reports.
That impressive rate was the result of an error, when a sub-group of about 2,700 trial subjects were given a half dose of the vaccine followed by a full booster dose, instead of the two full doses received by other participants.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
People in the sub-group were found to be the least likely to fall ill with Covid - but were all under the age of 55, and therefore less vulnerable to the coronavirus, health officials have revealed.
“The timeline for regulatory approval and rollout of the vaccine in the UK and Europe should not be affected” by the new testing push, The Guardian reports.
In the US, however, questions have been asked about whether AstraZeneca’s interim data tells the whole story.
“The problems start with the fact that Monday’s announcement did not present results from a single, large-scale, Phase 3 clinical trial,” says Wired. Instead, it included results from two separate trials, one in the UK and one in Brazil, which makes it hard to be sure researchers haven’t “cherry-picked the data”, the magazine adds.
AstraZeneca has pledged to publish its full results in a peer-reviewed journal as soon as possible.
Despite the urgency created by the mounting Covid-19 death toll, many experts have “called for patience”, Politico reports. Most believe that the full data will confirm the effectiveness of the Oxford vaccine.
And while some questions must still be answered, the recent vaccine trial results are “very good news”, says Professor Peter Openshaw of Imperial College London.
He told the BBC: “It is remarkable that each of the trials that are now reporting shows protection, which we did not know was going to be possible.”
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Holden Frith is The Week’s digital director. He also makes regular appearances on “The Week Unwrapped”, speaking about subjects as diverse as vaccine development and bionic bomb-sniffing locusts. He joined The Week in 2013, spending five years editing the magazine’s website. Before that, he was deputy digital editor at The Sunday Times. He has also been TheTimes.co.uk’s technology editor and the launch editor of Wired magazine’s UK website. Holden has worked in journalism for nearly two decades, having started his professional career while completing an English literature degree at Cambridge University. He followed that with a master’s degree in journalism from Northwestern University in Chicago. A keen photographer, he also writes travel features whenever he gets the chance.
-
Today's political cartoons - November 3, 2024
Cartoons Sunday's cartoons - presidential pitching, wavering convictions, and more
By The Week US Published
-
Why Man United finally lost patience with ten Hag
Talking Point After another loss United sacked ten Hag in hopes of success in the Champion's League
By The Week UK Published
-
Who are the markets backing in the US election?
Talking Point Speculators are piling in on the Trump trade. A Harris victory would come as a surprise
By The Week UK Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
Israel, UN agree to Gaza pauses for polio vaccinations
Speed Read Gaza's first case of polio in 25 years was confirmed last week in a 10-month-old boy who is now partially paralyzed
By Rafi Schwartz, The Week US Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published
-
Mpox: how dangerous is new health emergency?
Today's Big Question Spread of potentially deadly sub-variant more like early days of HIV than Covid, say scientists
By The Week UK Published
-
What is POTS and why is it more common now?
The explainer The condition affecting young women
By Devika Rao, The Week US Published
-
Brexit, Matt Hancock and black swans: five takeaways from Covid inquiry report
The Explainer UK was 'unprepared' for pandemic and government 'failed' citizens with flawed response, says damning report
By Harriet Marsden, The Week UK Published
-
Should masks be here to stay?
Talking Points New York Governor Kathy Hochul proposed a mask ban. Here's why she wants one — and why it may not make sense.
By Anya Jaremko-Greenwold, The Week US Published
-
Covid might be to blame for an uptick in rare cancers
The explainer The virus may be making us more susceptible to certain cancers
By Devika Rao, The Week US Published